Analysts Anticipate Infinity Pharmaceuticals Inc. (INFI) to Post -$0.25 EPS
Brokerages predict that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will announce earnings of ($0.25) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Infinity Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.22). Infinity Pharmaceuticals posted earnings per share of ($0.46) in the same quarter last year, which would indicate a positive year-over-year growth rate of 45.7%. The company is expected to issue its next earnings results on Tuesday, March 13th.
According to Zacks, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.93) per share for the current financial year, with EPS estimates ranging from ($0.95) to ($0.90). For the next financial year, analysts anticipate that the company will report earnings of ($1.07) per share, with EPS estimates ranging from ($1.10) to ($1.04). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.06. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $14.70 million. During the same quarter last year, the business earned ($0.39) EPS.
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) opened at $1.99 on Friday. Infinity Pharmaceuticals has a twelve month low of $0.93 and a twelve month high of $3.84.
In other news, insider Value Fund L. P. Biotechnology bought 1,600,046 shares of Infinity Pharmaceuticals stock in a transaction that occurred on Wednesday, October 4th. The shares were acquired at an average price of $1.26 per share, with a total value of $2,016,057.96. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Lawrence E. Bloch bought 500,000 shares of Infinity Pharmaceuticals stock in a transaction that occurred on Wednesday, December 6th. The stock was purchased at an average cost of $1.81 per share, for a total transaction of $905,000.00. Following the purchase, the president now owns 580,944 shares of the company’s stock, valued at $1,051,508.64. The disclosure for this purchase can be found here. Corporate insiders own 6.81% of the company’s stock.
Several large investors have recently made changes to their positions in INFI. Vanguard Group Inc. grew its stake in shares of Infinity Pharmaceuticals by 27.7% during the first quarter. Vanguard Group Inc. now owns 4,701,769 shares of the biotechnology company’s stock valued at $15,187,000 after buying an additional 1,021,128 shares during the last quarter. Platinum Investment Management Ltd. boosted its holdings in shares of Infinity Pharmaceuticals by 74.3% during the third quarter. Platinum Investment Management Ltd. now owns 1,411,832 shares of the biotechnology company’s stock worth $1,877,000 after purchasing an additional 601,600 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Infinity Pharmaceuticals during the first quarter worth about $1,588,000. Legal & General Group Plc boosted its holdings in shares of Infinity Pharmaceuticals by 2,430.0% during the second quarter. Legal & General Group Plc now owns 349,346 shares of the biotechnology company’s stock worth $548,000 after purchasing an additional 335,538 shares during the period. Finally, FMR LLC purchased a new stake in shares of Infinity Pharmaceuticals during the second quarter worth about $349,000. 54.41% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate Infinity Pharmaceuticals Inc. (INFI) to Post -$0.25 EPS” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/09/analysts-anticipate-infinity-pharmaceuticals-inc-infi-to-post-0-25-eps.html.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.